NCT02241200已完成1 期
A Randomized, 2 Part, 4-treatment, 2-way Cross-over Study in Healthy Volunteers to Compare the Pharmacokinetic and Pharmacodynamic Profiles of 1ug/kg of DA-3880 and EU Sourced ARANESP® (Amgen) After Single Intravenous or Subcutaneous Administration
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 64
- 试验地点
- 1
- 主要终点
- Pharmacokinetics of DA-3880 and Aranesp via SC Administration
研究概览
简要总结
The main purpose of the study is to determine whether the test product and the reference product are bioequivalent based on the pharmacokinetics after administration of ug/kg as a single intravenous dose and as a single subcutaneous dose of each of the formulations. The study is consisted of randomization, 2 parts, 4 treatments, 2 way cross over.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Gender : male or female
- •Age : 18 - 65 years, inclusive
- •Body Mass Index (BMI) : 18.0 - 30.0 kg/m2, inclusive
- •Weight : 55 - 105 kg, inclusive
- •Female subjects of childbearing potential must be non-pregnant and non-lactating, and have a negative pregnancy test at screening and (each) admission to the clinical research center
- •Females of child-bearing potential, with a fertile male sexual partner, should be willing to use adequate contraception from screening until 90 days after the follow-up visit. Adequate contraception is defined as using hormonal contraceptives or an intrauterine device combined with at least 1 of the following forms of contraception: a diaphragm or cervical cap, or a condom.
- •Males should be willing to use adequate contraception and not donate sperm from first admission to the clinical research center until 90 days after the follow-up visit. Adequate contraception for the male subject and his female partner, is defined as using hormonal contraceptives or an intrauterine device combined with at least 1 of the following forms of contraception: a diaphragm or cervical cap, or a condom.
- •All non-regular medication (including over the counter medication, health supplements, and herbal remedies such as St. John's Wort extract) must have been stopped at least 14 days prior to (the first) admission to the clinical research center. An exception is made for paracetamol (acetaminophen), which is allowed up to admission to the clinical research center. Other exceptions are multivitamins and vitamin C, which are allowed up to 7 days before admission to the clinical research center.
- •All regular non-topical medication must have been stopped at least 30 days prior to (the first) admission the clinical research center. An exception is made for hormonal contraceptives, which may be used throughout the study.
- •Ability and willingness to abstain from alcohol, methylxanthine-containing beverages or food (coffee, tea, cola, chocolate, "powerdrinks"), grapefruit (juice) and tobacco products from 48 h prior to each admission to in the clinical research center
- •Medical history without major pathology as judged by the PI
- •Normal resting supine blood pressure and pulse showing no clinically relevant deviations as judged by the PI.
- •Computerized (12-lead) electrocardiogram (ECG) recording without signs of clinically relevant pathology or showing no clinically relevant deviations as judged by the PI.
- •All values for clinical laboratory tests of blood and urine within the normal range or showing no clinically relevant deviations as judged by the PI. Hb, Hct, RBC count and thrombocytes should not exceed the upper limit of normal. Minor deviations can be accepted at the discretion of the PI
- •Willing and able to sign the ICF
排除标准
- •Evidence of clinically relevant pathology
- •Mental handicap
- •History of relevant drug and/or food allergies, and/or latex allergy
- •Smoking more than 10 cigarettes, 2 cigars or 2 pipes daily; the use of tobacco products in the 48 hours (2 days) prior to each admission to the clinical research center is not allowed.
- •History of alcohol or drug abuse or drug addiction (including soft drugs like cannabis products)
- •Positive drug screen (opiates, methadone, cocaine, amphetamines [including ecstasy], cannabinoids, barbiturates, benzodiazepines, tricyclic antidepressants and alcohol)
- •Average intake of more than 24 units of alcohol per week: one unit of alcohol equals approximately 250 mL of beer, 100 mL of wine or 35 mL of spirits)
- •Consumption of any foods containing poppy seeds within 48 hours (2 days) prior to each admission to the clinical research center as this could cause a false positive drug screen result
- •Positive screen on hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) antibodies or anti-HIV 1 and 2 antibodies
- •Participation in a drug study within 60 days prior to the screening visit in the current study. Participation in more than 3 other drug studies (for men) and more than 2 other drug studies (for women) in the 10 months prior to the first drug administration in the current study
- •Donation or loss of more than 100 mL of blood within 60 days prior to the first drug administration. Donation or loss of more than 1.5 liters of blood (for men) / more than 1.0 liters of blood (for women) in the 10 months prior to the first drug administration in the current study.
- •Strenuous exercise within 96 hours (4 days) prior to each admission to the clinical research center.
- •Significant and/or acute illness within 5 days prior to the first drug administration that may impact safety assessments, in the opinion of the PI
- •Vaccination within 30 days prior to entry into the clinical research center or planning a vaccination before the follow-up visit
- •History of a significant respiratory disorder (such as asthma) or significant immune disorder
- •Significant infection within 30 days prior to entry into the clinical research center
- •History of epilepsy; a single febrile convulsion at an age < 6 years is acceptable
- •History of hemoglobinopathy or abnormal Hb in first-degree relatives
- •A previous administration of any erythropoiesis-stimulating agent including EPO or darbepoetin, if known
- •Previous immunoglobulin or iron supplementation within 3 months prior to the screening visit
- •History of hypersensitivity reactions for any EPO, darbepoetin, iron supplements, or excipient of the investigational product
研究组 & 干预措施
IV Administration
Experimental
The iv solutions containing DA-3880 and Aranesp will be indistinguishable in appearance.
干预措施: DA3880 (Drug)
IV Administration
Experimental
The iv solutions containing DA-3880 and Aranesp will be indistinguishable in appearance.
干预措施: Aranesp (Drug)
SC Administration
Experimental
The sc solutions containing DA-3880 and Aranesp will be indistinguishable in appearance.
干预措施: DA3880 (Drug)
SC Administration
Experimental
The sc solutions containing DA-3880 and Aranesp will be indistinguishable in appearance.
干预措施: Aranesp (Drug)
结局指标
主要结局
Pharmacokinetics of DA-3880 and Aranesp via SC Administration
时间窗: 6 weeks
AUC0-t, Cmax, Tmax, t½, AUC0-inf, %AUC of DA-3880 and EU sourced Aranesp® (Amgen) after administration of 1 μg/kg as a single sc dose will be assessed
Pharmacokinetics of DA-3880 and Aranesp via IV Administration
时间窗: 6 weeks
AUC0-t, Cmax, Tmax, t½, AUC0-inf, %AUC of DA-3880 and EU sourced Aranesp® (Amgen) after administration of 1 μg/kg as a single iv dose will be assessed.
次要结局
- Pharmacodynamic Variables of DA-3880 and Aranesp(6 weeks)
- Safety and Tolerability Parameters of SC and IV Administration(6 weeks)
- Safety and Tolerability Parameters of DA-3880 and Aranesp(6 weeks)
- Pharmacodynamic and Pharmacodynamic Variables of IV and SC Administration(6 weeks)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Bioavailability Study of 300 mg Trazodone Hydrochloride (New Polymer) vs. 300 mg Trazodone Hydrochloride (Contramid® Prolonged-release Tablets) Under Fasting ConditionsHealthyNCT05136521Aziende Chimiche Riunite Angelini Francesco S.p.A28
已完成
3 期
Clinical Endpoint Bioequivalence Study of Test and Reference Inhalation Products in Patients With COPD With Device RobustnessChronic Obstructive Pulmonary DiseaseNCT03137992Lupin, Inc.377
已完成
3 期
Equivalence Study of Dorzolamide 2% Eye Drops SolutionOpen Angle GlaucomaOcular HypertensionNCT00878917Alfred E. Tiefenbacher (GmbH & Co. KG)32
已完成
1 期
Bioequivalence Pilot Study of Dirithromycin of (Abdi İbrahim İlaç San.Ve.Tic.A.Ş,Turkey) in Healthy Subjects Under Fasting ConditionHealthyNCT02185833Pharmaceutical Research Unit, Jordan12
已完成
1 期
Bioequivalence Pilot Study of Dirithromycin of (Abdi İbrahim İlaç San.Ve.Tic.A.Ş,Turkey) in Healthy Subjects Under Fed ConditionHealthyNCT02185846Pharmaceutical Research Unit, Jordan12